Journal of Clinical Psychopharmacology最新文献

{"title":"The Synergistic Effect of Bupropion-Dextromethorphan With Thyroid Supplementation in Treatment-Resistant Depression: A Case Report.","authors":"Adam Fijtman, Rachel A Rans, Kelly T Hurst, Carlos A Zarate, Elizabeth D Ballard","doi":"10.1097/JCP.0000000000002091","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002091","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of Evidence and an Algorithm for Use of Psychopharmacology in the Treatment of Tobacco Use Disorder in Behavioral Health Settings.","authors":"Afrah Mohammad, Christoforos Iraklis Giakoumatos, Naim Mekdessi, David N Osser","doi":"10.1097/JCP.0000000000002057","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002057","url":null,"abstract":"<p><strong>Background: </strong>Tobacco use poses a large public health problem, particularly among those with mental illness, but behavioral health providers often do not prioritize management of this disorder.</p><p><strong>Methods: </strong>This is a new algorithm from the Psychopharmacology Algorithm Project at the Harvard South Shore Program for the treatment of tobacco use disorder, taking into account pertinent findings in articles, meta-analyses, reviews, and other published algorithms.</p><p><strong>Results: </strong>Once patients are prepared to try medications, we first consider exceptions to the main algorithm when there is comorbid major depressive disorder, bipolar disorder, other serious mental illnesses, posttraumatic stress disorders, alcohol use disorder, cardiovascular morbidity, seizure disorders, or weight gain that could affect the choice of pharmacological agents. In patients with depression, bupropion could be considered as initial treatment, while bupropion should usually be avoided in patients with bipolar disorder and is relatively contraindicated in those with a seizure disorder. In the main algorithm, for patients who smoke cigarettes, varenicline has been convincingly established as the most effective treatment, with combined nicotine replacement therapy as a potential second-choice consideration. In the event of unsatisfactory response to varenicline after an adequate trial (described in detail), augmentation with bupropion may be considered; the role of combination therapy (eg, varenicline + NRT) is less well established and is discussed in the context of limited evidence. For users of smokeless tobacco, the evidence is also in favor of using varenicline first-line. Management of the side effects of these medications is discussed.</p><p><strong>Conclusions: </strong>The algorithm concludes with a discussion of other options with less support but with potential future promise.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Case Series Assessing the Potential Interaction Between Lithium and Sodium-Glucose Cotransporter-2 Inhibitors.","authors":"John Powers, Balwinder Singh, Lauren R Stonerock, Jonathan G Leung","doi":"10.1097/JCP.0000000000002069","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002069","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Question: Does Cinnamon Interfere With Antidepressant Metabolism?","authors":"Richard I Shader","doi":"10.1097/JCP.0000000000002093","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002093","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.","authors":"Majd Al-Soleiti, Jonathan G Leung, Teeba Mubaydeen, Matej Markota, Osama Abulseoud, Balwinder Singh, Christopher L Sola","doi":"10.1097/JCP.0000000000002090","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002090","url":null,"abstract":"<p><strong>Background: </strong>Lithium is a mainstay treatment for bipolar disorder, but its narrow therapeutic index and susceptibility to pharmacokinetic interactions make appropriate monitoring crucial. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are increasingly prescribed for type 2 diabetes and weight management. Scarce evidence exists on the potential interaction between semaglutide and lithium.</p><p><strong>Methods: </strong>We present 3 cases involving patients on stable lithium regimens who were initiated on semaglutide, reviewing potential mechanisms underlying the interaction between them.</p><p><strong>Findings: </strong>In 2 cases, lithium levels increased significantly, leading to toxicity despite stable renal function and no changes in concurrent medications. In the third case, preemptive reductions in lithium dosage mitigated toxicity, although lithium levels remained higher than anticipated. Mechanistic hypotheses that might contribute to semaglutide-associated elevated lithium levels include altered kidney function, dehydration from reduced oral intake, vomiting, or diarrhea, and delayed gastric emptying.</p><p><strong>Conclusions: </strong>To our knowledge, this is one of the first documented case series describing a potential interaction between semaglutide and lithium in the medical literature. These cases underscore the importance of vigilant monitoring when combining lithium with semaglutide, and potentially other GLP-1 RAs. Baseline renal function, hydration status, and lithium levels should be assessed before initiating semaglutide, and lithium levels should be monitored more frequently during therapy. Clinicians prescribing semaglutide to patients on lithium should exercise caution, monitor for signs of toxicity, and provide appropriate patient education. Further research is needed to elucidate the mechanisms of this potential interaction and its clinical significance.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diet Drug Interactions: Achieving and Maintaining Ketosis As Adjunct to Psychotropic Polypharmacotherapy.","authors":"Dina N Ali, Mark A Frye, Iain H Campbell, Matej Markota, Mikaela M Hofer, Heather Standorf, Jonathan G Leung","doi":"10.1097/JCP.0000000000002074","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002074","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol-Induced Obsessive-Compulsive Disorder: A Case Report With Neurobiological and Clinical Insights.","authors":"Mahak Aggarwal, Avnika Bansal, Nishant Singh Dhillon, Mohit Thakur, Jawahar Singh","doi":"10.1097/JCP.0000000000002094","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002094","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.","authors":"John L Havlik, Sayana Isaac, Pralahad Raman, Nathan Tran, Kalea Hidalgo, Trisha Suppes","doi":"10.1097/JCP.0000000000002095","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002095","url":null,"abstract":"<p><strong>Background: </strong>With a rapid rise in clinical trials investigating psychogenic substances, the field faces considerable concerns regarding transparency and conflicts of interest. This study aims to systematically characterize ongoing NIH-registered clinical trials investigating psychogenic substances for psychiatric disorders as of late 2024, including research protocols, institutional settings, and funding sources.</p><p><strong>Procedures: </strong>This cross-sectional analysis evaluated ongoing trials from ClinicalTrials.gov that studied psychogenic substances-defined as compounds significantly affecting perception, cognition, or emotion-for psychiatric conditions. Data collected included substance class, targeted diagnoses, trial phase, geographic location, study design (eg, blinding), recruitment status, and funding sources.</p><p><strong>Findings: </strong>A total of 181 trials met the inclusion criteria, with the majority in phase 2 (n=93; 51.4%) or phase 1 (n=33; 18.2%). The most frequently studied substances were psilocybin (n=64; 35.4%) and ketamine (n=61; 33.7%). Trials were notably concentrated within a small number of leading academic institutions. Most trials (n=148; 81.2%) listed their funding source as \"other,\" of which 127 (86.4%) were sponsored by universities or university-affiliated institutions. Blinding was not reported in 38.7% (n=70) of trials. The primary conditions studied were major depressive disorder (n=94; 51.9%), posttraumatic stress disorder (n=38; 21.0%), and alcohol use disorder (n=21; 11.6%).</p><p><strong>Implications: </strong>Ongoing clinical trials of psychogenic substances for psychiatric disorders are largely concentrated at select institutions and primarily focus on psilocybin and ketamine. The majority lack clear disclosure of funding sources, highlighting a need for enhanced transparency to build trust and facilitate the ethical advancement of this rapidly evolving area of psychiatric research.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genital Hair Growth in a Young Girl Treated With Methylphenidate for Attention Deficit Hyperactivity Disorder: A Case Report.","authors":"Ayşegül Tuğba Hira Selen, Ömer Faruk Akça","doi":"10.1097/JCP.0000000000002071","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002071","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis.","authors":"Rachel E Landrum, Amanda M Raines, Philip D Harvey, Michael D Banov, Kevin G Saulnier, Michelle B Moore","doi":"10.1097/JCP.0000000000002060","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002060","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to assess the effects of intravenous racemic ketamine on global depression severity and individual depressive symptoms in patients with treatment-resistant depression.</p><p><strong>Methods: </strong>This retrospective, exploratory cohort study includes 74 consecutive adult patients treated in an outpatient specialty psychiatric clinic with serial racemic ketamine infusions for treatment-resistant depression between April 2019 and May 2023. Depression symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale and Patient-Health Questionnaire-9 over 10 treatment sessions. Adverse effects were captured during treatment. Analyses considered changes in individual item and total depression rating scale scores, as well as the proportion of cases who manifested clinical response (change of >49%) and remission at each studied time point.</p><p><strong>Results: </strong>Results revealed significant and persistent reductions over time in both Montgomery-Åsberg Depression Rating Scale and Patient-Health Questionnaire-9 total scores, as well as in all individual items on both scales (all Ps < 0.001). Depression rating scale scores did not significantly change from treatment session 4 to session 10. Side effect burden was no greater in higher doses as compared with lower.</p><p><strong>Conclusions: </strong>Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression as demonstrated by reductions in Montgomery-Åsberg Depression Rating Scale and Patient-Health Questionnaire-9 total scores and equivocal changes in every item on both rating scales. The magnitude of change in individual items was similar to that of previous randomized trials, with suicidal ideation and depression demonstrating the largest response and appetite disturbance the least.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}